Highbridge Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Highbridge Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-13,504	Closed	-$59K	–	1494
2018 Q1	$59K	Buy	+13,504	New	+$60.3K	﹤0.01%	1117
2017 Q3	–	Sell	-13,608	Closed	-$98K	–	1911
2017 Q2	$98K	Buy	13,608 +602	+5%	+$3.7K	﹤0.01%	1172
2017 Q1	$69K	Buy	+13,006	New	+$87.8K	﹤0.01%	1392
2016 Q1	–	Sell	-144,994	Closed	-$809K	–	1982
2015 Q4	$809K	Buy	+144,994	New	+$958K	0.01%	827
2015 Q1	–	Sell	-26,609	Closed	-$474K	–	1695
2014 Q4	$474K	Buy	+26,609	New	+$332K	0.01%	835

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Highbridge Capital Management's PETX Position: Q2 2018 in Review

Highbridge Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2018, closing a stake of 13,504 shares — an estimated $59K sold.

Highbridge Capital Management first reported a position in PETX in Q4 2014 and held it in 5 quarters. The position peaked at $809K in Q4 2015. 105 funds tracked by Wall St. Rank hold PETX as of Q2 2018.

Highbridge Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 13,504 Aratana Therapeutics, Inc. shares in Q2 2018, an estimated $59K.
Highbridge Capital Management first reported a position in Aratana Therapeutics, Inc. in Q4 2014 and held it in 5 quarters.
Highbridge Capital Management's Aratana Therapeutics, Inc. position peaked at $809K in Q4 2015.
105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.